genomewid
rna
interfer
rnai
proven
power
tool
identifi
host
molecul
particip
step
viru
replic
metaanalysi
find
genomewid
rnai
screen
shown
influenza
viru
depend
function
node
host
cell
pathway
requir
wide
varieti
molecul
cellular
protein
replic
rapid
evolut
influenza
virus
persist
complic
effect
vaccin
therapeut
understand
complex
host
cell
pathway
coopt
influenza
viru
replic
may
provid
new
target
strategi
antivir
therapi
rnai
genom
screen
technolog
togeth
bioinformat
provid
abil
rapidli
identifi
specif
host
factor
involv
resist
suscept
influenza
viru
allow
novel
diseas
intervent
strategiesmeliopoulo
target
novel
influenza
therapi
elucid
highthroughput
rna
interfer
screen
faseb
j
wwwfasebjorg
genic
influenza
virus
continu
emerg
exhibit
mortal
rate
human
outbreak
highlight
persist
devast
natur
influenza
infect
increas
risk
new
pandem
despit
scientif
advanc
past
decad
eid
continu
inflict
substanti
social
econom
cost
exampl
influenza
lead
caus
morbid
mortal
world
season
virus
affect
human
popul
caus
sever
ill
million
peopl
fatal
individualsyr
coupl
econom
burden
associ
widespread
influenza
infect
unit
state
alon
financi
loss
result
season
influenza
infect
estim
exceed
billion
annual
abil
influenza
virus
continu
mutat
made
control
strategi
base
vaccin
difficult
simultan
resist
current
antivir
increas
reason
new
strategi
combat
eid
influenza
requir
expand
knowledg
hostviru
interact
crucial
first
step
despit
complex
influenza
biolog
virus
class
contain
gene
segment
therefor
lack
full
complement
protein
requir
produc
infecti
viru
influenza
like
virus
must
coopt
wide
array
host
protein
noncod
rna
cellular
process
exampl
transport
vesicl
gener
infecti
viral
particl
replic
cycl
orthomyxovirus
divid
earli
middl
late
stage
earli
stage
involv
event
link
viru
bind
via
hemagglutinin
ha
sialic
acid
moieti
found
host
cell
membran
intern
viral
particl
midstag
event
includ
express
translat
viral
gene
late
event
compris
viru
protein
traffick
cell
membran
virion
assembl
bud
cell
understand
host
contribut
viral
replic
immun
evas
essenti
discov
new
therapeut
strategi
genom
screen
technolog
use
rna
interfer
rnai
togeth
bioinformat
provid
abil
rapidli
identifi
complement
essenti
host
function
pathway
essenti
viru
rnai
natur
sequencespecif
posttranscript
gene
silenc
pathway
fig
present
eukaryot
compon
rnai
pathway
serv
multipl
role
vari
differ
organ
one
hand
element
pathway
particip
innat
immun
respons
recogniz
figur
rnai
pathway
endogen
mirna
transcrib
primirna
subsequ
process
drosha
dicer
gener
matur
mirna
guid
strand
incorpor
rnainduc
silenc
complex
risc
facilit
gene
silenc
reagent
develop
screen
includ
express
construct
shrna
shrnamir
well
synthet
construct
sirna
mirna
mimic
mirna
inhibitor
ing
degrad
long
doublestrand
rna
dsrna
typic
associ
viral
infect
simultan
rnai
pathway
recogn
role
regul
host
gene
express
relat
myriad
cell
function
guid
matur
transcript
target
capabl
uniqu
class
noncod
rna
call
microrna
mirna
ref
aspect
rnai
particularli
intrigu
given
virus
particular
herpesvirus
encod
mirna
regul
host
gene
express
therefor
critic
role
dynam
hostpathogen
interact
outsid
import
role
gene
modul
rnai
pathway
recogn
preemin
mean
studi
gene
function
regard
research
creat
entir
librari
genespecif
target
reagent
silenc
individu
gene
function
enter
pathway
one
two
distinct
posit
one
instanc
synthet
dsrna
reagent
refer
small
interf
rna
sirna
gener
introduc
cell
sirna
associ
rnainduc
silenc
complex
risc
sirna
guid
strand
anneal
complementari
target
mrna
facilit
cleavag
argonaut
core
endonucleas
risc
fig
altern
approach
research
develop
collect
genetarget
short
hairpin
rna
shrna
gener
plasmid
viral
express
construct
like
endogen
mirna
counterpart
shrna
express
nucleu
predict
associ
risc
process
two
separ
endonucleas
drosha
dicer
fig
ref
complex
rnai
screen
hostpathogen
interact
requir
thought
consider
silenc
reagent
cell
line
viru
use
rnai
screen
typic
begin
plate
target
cell
introduct
silenc
reagent
sirnabas
studi
screen
gener
perform
array
format
individu
gene
target
anywher
sirnaswel
case
pool
reagent
prefer
provid
cumul
silenc
effect
greatli
increas
efficaci
gene
knockdown
synthet
silenc
reagent
introduc
via
forward
revers
transfect
protocol
mani
cell
type
lead
effici
intracellular
deliveri
sirna
case
shrna
use
express
viral
construct
one
two
approach
employ
first
shrna
workflow
parallel
sirna
screen
process
adopt
array
platform
altern
shrna
screen
often
make
use
pool
viral
particl
contain
express
construct
target
hundr
thousand
gene
scenario
cell
plate
follow
viru
transduct
low
multipl
infect
thu
ensur
infect
cell
receiv
one
viral
particl
drug
select
follow
transduct
elimin
cell
carri
genetarget
construct
pool
shrna
screen
best
suit
output
assay
permit
select
outgrowth
cell
exhibit
phenotyp
interest
specif
shrna
influenc
phenotyp
consequ
enrich
deplet
popul
identifi
either
microarray
nextgener
sequenc
ng
overview
compar
workflow
sirna
vs
shrna
see
tabl
regardless
type
silenc
reagent
employ
cell
subsequ
cultur
period
time
allow
gene
knockdown
account
uniqu
attribut
screen
instanc
intent
screen
studi
viral
uptak
infect
may
delay
avoid
lipidmedi
sirna
transfect
affect
abil
viru
bind
cell
cell
infect
viru
choic
cultur
addit
period
time
assay
one
techniqu
eg
transcript
report
viral
titer
determin
effect
gene
knockdown
variou
aspect
viral
life
cycl
worth
note
differ
silenc
reagent
permit
differ
type
assay
incorpor
workflow
although
period
gene
silenc
provid
sirna
vari
gene
cell
type
studi
synthet
sirna
gener
provid
gene
knockdown
reagent
compat
assay
perform
within
brief
window
contrast
shrna
express
construct
deliv
lentiviru
stabli
integr
host
genom
permit
assay
extend
beyond
transient
sirna
window
perform
rnai
screen
util
sirna
technolog
greatli
aid
autom
extrem
accuraci
reproduc
extent
speed
necessari
manag
sirna
librari
resourc
dispens
aspir
cell
medium
perform
lipidmedi
transfect
screen
involv
infecti
reagent
liquid
handl
platform
modular
attract
facilit
separ
step
requir
highlevel
biocontain
common
rnai
screen
screen
process
iter
full
genomewid
screen
take
anywher
week
month
depend
assay
complex
level
autom
particular
pathogen
investig
logist
use
divid
screen
genesilenc
collect
regard
hit
identif
term
use
identifi
gene
silenc
signific
effect
function
assay
number
bioinformat
approach
describ
one
instanc
factor
calcul
determin
distinct
posit
neg
control
subsequ
z
score
method
normal
mean
valu
sampl
plate
commonli
use
rank
gene
candid
gene
categor
defin
featur
valid
statist
enrich
target
rel
refer
popul
rank
valid
mani
paramet
may
captur
screen
weight
import
principl
screen
phenotyp
classifi
distinct
bin
refin
gene
list
prior
valid
exampl
shrna
screen
follow
ng
analysi
data
subject
statist
enrich
target
rel
refer
popul
result
rank
list
identifi
target
valid
sirna
librari
construct
varieti
design
reagent
use
rang
studi
cell
type
import
consid
tool
best
suit
hostpathogen
screen
one
potenti
relev
consider
center
activ
cellular
immun
pathway
well
document
viral
infect
monitor
pathogen
recognit
receptor
prr
trigger
innat
immun
respons
upon
identifi
evolutionarili
conserv
pathogenassoci
molecular
pattern
pamp
exampl
recognit
influenza
singlestrand
rna
genom
endosom
prr
tolllik
receptor
lead
strong
antivir
cytokin
respons
previou
studi
also
shown
transfect
short
dsrna
sirna
also
perturb
cellular
immun
exampl
demonstr
sirna
longer
bp
strongli
upregul
interferon
ifn
stimul
gene
hela
cell
group
shown
sirna
activ
type
interferon
respons
particularli
thu
sirna
viru
independ
stimul
tlr
pathway
question
aris
one
effect
screen
host
gene
play
role
viru
replic
one
solut
may
lie
reagent
select
exampl
sirna
design
complet
complementar
target
transcript
one
design
variabl
duplex
length
previou
studi
shown
cell
type
short
bp
sirna
effect
silenc
gene
weaker
activ
tlr
signal
pathway
certain
circumst
reagent
minim
immun
stimulatori
effect
would
otherwis
complic
rnai
screen
involv
pathogen
addit
sever
group
demonstr
modif
particular
nucleotid
defin
chemic
group
greatli
reduc
immunostimulatori
effect
sirna
modif
act
either
ci
tran
limit
activ
therebi
prevent
trigger
downstream
interferon
cytokin
pathway
separ
anoth
noteworthi
caveat
rnai
screen
sirna
specif
extens
studi
shown
addit
target
mrna
interest
sirna
act
similar
fashion
mirna
attenu
translat
dozen
gene
fals
posit
refer
offtarget
induc
mechan
frequent
mediat
shrna
sirna
screen
stage
broken
chronolog
order
stage
take
differ
time
depend
assay
quantit
method
bioinformat
analysi
ongo
effort
interven
screen
process
sever
point
central
screen
platform
identif
robust
posit
neg
control
sirna
platform
siglo
fluoresc
report
use
indic
transfect
effici
seed
region
sirna
nt
may
result
downregul
unintend
target
notabl
offtarget
gener
thought
gene
encod
cell
case
rnai
screen
design
identifi
hostpathogen
interact
offtarget
also
includ
gene
encod
pathogen
multipl
approach
develop
minim
effect
offtarget
includ
chemic
modif
sirna
duplex
reduc
seedmedi
gene
silenc
exampl
modif
second
nucleotid
sirna
antisens
strand
greatli
reduc
seedmedi
offtarget
effect
use
reagent
primari
screen
minim
number
fals
posit
therebi
reduc
time
cost
associ
downstream
valid
altern
case
pool
sirna
use
primari
screen
deconvolut
pool
demonstr
multipl
individu
sirna
differ
seed
sequenc
give
phenotyp
increas
level
confid
phenotyp
relat
knockdown
target
gene
lastli
bioinformat
effect
use
identifi
offtarget
effect
crosscheck
seed
sequenc
sirna
induc
phenotyp
seed
known
mirna
host
pathogen
often
identifi
instanc
one
sirna
mimick
mirna
although
hit
exclud
studi
due
potenti
interest
host
mirnapathogen
interact
may
indic
observ
phenotyp
result
event
unrel
knockdown
intend
target
gene
similar
consider
may
relev
perform
screen
shrna
express
cassett
case
shrna
gener
dnabas
express
construct
predomin
collect
shrna
librari
use
either
lentivir
retrovir
deliveri
system
facilit
entri
integr
cassett
host
genom
previou
genom
profil
studi
lentivir
hiv
infect
cell
shown
infect
lead
differenti
express
multipl
gene
categori
includ
relat
complement
activ
actin
filament
proteasom
core
thu
although
current
shrna
platform
essenti
perform
hostpathogen
studi
case
cell
type
choic
refractori
lipidmedi
transfect
extend
period
gene
knockdown
requir
one
must
consid
potenti
contribut
deliveri
platform
outcom
hostpathogen
screen
mirna
mirna
emerg
essenti
regul
eukaryot
gene
express
matur
mirna
sequenc
found
speci
includ
virus
identifi
human
recent
studi
identifi
host
viral
encod
mirna
critic
element
regul
viru
replic
exampl
human
identifi
essenti
compon
affect
biolog
hepat
c
viru
replic
interestingli
procytomegaloviru
procmv
anticmv
mirna
identifi
encod
mous
genom
studi
emphas
need
mirna
screen
accompani
sirna
shrna
screen
target
proteincod
gene
identifi
hostencod
mirna
relev
viral
infect
gener
involv
twoprong
approach
synthet
mirna
mimic
equival
set
reagent
express
eg
plasmid
viralbas
vector
use
increas
cellular
concentr
given
mirna
contrast
mirna
inhibitor
design
matur
mirna
act
artifici
target
prevent
endogen
mirna
interact
natur
target
librari
mimic
inhibitor
recent
use
identifi
mirna
play
role
divers
herp
viru
infect
murin
cmv
mcmv
murin
herp
herp
simplex
ref
evalu
phenotyp
effect
induc
mimic
correspond
inhibitor
studi
abl
identifi
antivir
provir
mirna
act
across
divers
virus
analysi
implic
mirna
varieti
host
signal
network
includ
extracellular
regul
kinas
erk
mitogenactiv
protein
kinas
mapk
phosphatidylinositol
akt
signal
among
other
pathway
also
implic
influenza
infect
find
suggest
mirna
might
broad
therapeut
potenti
prospect
diseas
intervent
strategi
scope
mani
screen
translat
cell
type
chosen
often
qualiti
consist
evalu
druggabl
pharmacokinet
cytotox
properti
far
practic
research
tri
use
cell
type
repres
biolog
interest
exampl
lung
cell
line
investig
influenza
infect
full
genomewid
rnai
screen
primari
cell
often
impract
reason
screen
util
immort
cell
line
gener
cell
amen
standard
transfectiontransduct
procedur
use
rnai
screen
recogn
cell
line
maintain
cultur
long
period
time
significantli
alter
genom
epigenom
transcriptom
truth
differ
may
one
largest
contributor
screentoscreen
variat
observ
across
hostpathogen
studi
reason
put
hit
identifi
primari
screen
often
valid
use
counterscreen
employ
altern
cell
type
relat
virus
sirna
shrna
target
differ
seed
site
gene
smallmolecul
inhibitor
known
target
gene
interest
iter
process
design
identifi
candid
gene
vivo
test
ultim
clinic
studi
final
worth
note
qualiti
assur
qualiti
control
cell
line
particularli
import
hostpathogen
screen
recogn
cell
line
deriv
rang
sourc
contamin
pathogen
mycoplasma
given
focu
hostpathogen
screen
possibl
contamin
pathogen
augment
cellular
physiolog
frequent
test
cell
cultur
cours
screen
valid
necessari
minim
possibl
underli
contamin
alter
screen
output
virus
grow
rapidli
capabl
accumul
mutat
eg
point
mutat
delet
short
period
time
dna
virus
gener
genet
stabl
rna
virus
due
cellular
error
correct
mechan
dna
mutat
either
viral
class
result
defect
progeni
refer
defect
interf
di
particl
lack
necessari
complement
gene
infect
replic
featur
dramat
alter
output
interpret
rnai
screen
studi
design
identifi
hostpathogen
interact
use
lowpassag
viral
particl
recent
isol
stock
one
scenario
viru
investig
may
seriou
concern
human
andor
anim
health
therefor
subject
highlevel
biosafeti
contain
case
viru
may
requir
enhanc
contain
biosafeti
level
bsl
use
biosafeti
cabinet
isol
person
protect
equip
includ
hepafilt
exhaust
air
minim
impact
restrict
assay
workflow
rnai
screen
util
highlevel
pathogen
limit
amount
work
perform
highest
level
contain
perform
sirna
transfect
cell
handl
regular
laboratori
move
cell
high
biocontain
infect
phase
infect
period
complet
protocol
allow
virusinfect
plate
decontamin
remov
allow
function
readout
perform
outsid
contain
approach
taken
screen
chemic
compound
librari
inhibitor
hendra
viru
absenc
biocontain
facil
one
way
studi
highrisk
virus
lower
biosafeti
level
eg
use
pseudotyp
virus
recombin
model
virus
construct
replac
nativ
envelop
glycoprotein
level
viru
eg
vesicular
stomat
viru
envelop
glycoprotein
highrisk
viru
interest
eg
ebola
pseudotyp
virus
mimic
viral
entri
process
origin
viru
compet
singl
cycl
infect
shortcom
associ
use
pseudovir
particl
envelop
protein
incorpor
carrier
viru
valu
investig
postentri
process
limit
research
gain
valuabl
inform
regard
hostencod
viral
receptor
endocyt
pathway
facilit
viral
entri
subsequ
step
replic
may
mask
virus
use
vaccin
develop
highli
pathogen
influenza
viru
ebola
lassa
hemorrhag
fever
viru
mean
work
around
biosafeti
issu
work
wildtyp
virus
date
rnai
screen
incorpor
variabl
methodolog
endpoint
perform
detect
host
contribut
influenza
replic
screen
focus
earli
replic
event
other
includ
earli
late
event
furthermor
screen
examin
differ
subset
host
gene
util
unrel
cell
model
rang
permiss
cell
cell
influenza
natur
infect
screen
gener
list
potenti
relev
host
gene
repres
screen
gene
except
shapira
et
al
focus
gene
previous
implic
yeast
studi
therefor
observ
significantli
higher
hit
rate
observ
sever
hostpathogen
rnai
screen
candid
identifi
across
screen
littl
overlap
overal
gene
independ
valid
screen
gene
valid
screen
gene
valid
across
screen
tabl
absenc
overlap
influenza
screen
hit
list
suggest
ident
specif
cellular
factor
involv
respons
influenza
viru
infect
context
depend
influenc
experiment
factor
vari
screen
screen
support
observ
hit
list
identifi
karla
et
al
konig
et
al
use
cell
viru
show
highest
degre
overlap
given
factor
includ
differ
sourc
media
serum
variabl
chromosom
insert
posit
report
construct
inconsist
silenc
effici
differ
sirna
collect
may
contribut
observ
dispar
global
approach
screen
analysi
requir
context
hostpathogen
rnai
screen
gener
come
form
metaanalysi
includ
indepth
literatur
review
program
ingenu
pathway
analysi
other
identifi
signific
network
top
function
canon
pathway
associ
differ
gene
hit
uncov
screen
provid
biolog
insight
interact
gene
protein
chemic
pathway
cellular
phenotyp
diseas
process
ob
serv
pathway
fidel
analysi
suggest
conserv
set
core
process
robust
experiment
variabl
may
coopt
influenza
viru
infect
replic
mammalian
cell
exampl
subset
process
identifi
mean
includ
follow
host
cell
signal
pathway
within
host
cell
major
mechan
transmit
extracellular
signal
intracellular
signal
engag
rtk
fig
among
famili
rtk
group
epiderm
growth
factor
receptor
egfr
consist
four
member
egf
receptor
ref
erbb
express
associ
multitud
cellular
function
respons
includ
prolifer
cell
migrat
differenti
apoptosi
cellular
endocytosi
influenza
coopt
pathway
use
egfr
result
protein
ubiquitinyl
sort
vacuolar
pathway
addit
influenza
viru
particl
sort
popul
late
endosom
egfr
specif
inhibit
tyrosin
kinas
smallmolecul
inhibitor
well
specif
egfr
inhibit
via
rnai
reduc
viru
uptak
subsequ
viru
titer
furthermor
attach
influenza
viru
host
cell
caus
cluster
plasma
membran
lipid
similar
seen
follow
egf
stimul
therefor
influenza
viru
bind
host
cell
sialic
acid
abl
cluster
activ
egfr
rtk
form
lipid
raftbas
signal
platform
lead
receptormedi
signal
event
enhanc
influenza
viru
uptak
subsequ
viral
replic
thought
activ
mediat
viral
engag
particular
receptor
kinas
gener
phenomenon
affect
sever
rtk
addit
support
result
recent
sirna
screen
studi
identifi
involv
fibroblast
growth
factor
receptor
fgfr
rtk
earli
step
viral
infect
therefor
influenza
viru
entri
accompani
downregul
signal
receptor
promot
coendocytosi
viru
host
cell
pkc
belong
larg
famili
serinethreonin
kinas
involv
multitud
physiolog
process
pkc
play
integr
role
sodium
ion
transport
import
maintain
low
ph
endosom
pkc
also
shown
critic
entri
envelop
virus
via
receptormedi
endocytosi
upon
influenza
viru
infect
ha
rapidli
activ
pkc
shown
specif
inhibitor
pkc
prevent
influenza
viru
replic
inhibit
entri
viru
similarli
influenza
viru
replic
also
report
cell
express
phosphorylationdefici
form
pkc
host
signal
factor
bind
host
cell
sialic
acid
influenza
viru
activ
rtk
form
lipid
raftbas
signal
platform
enhanc
influenza
uptak
cell
prolifer
hamedi
activ
protein
kinas
c
pkc
also
aid
viral
entri
cellular
prolifer
rtk
activ
phosphatidylinositol
signal
inhibit
cellular
apoptosi
rafmekerk
cascad
downstream
rtk
requir
effici
nuclear
export
viral
ribonucleoprotein
viral
manipul
nfb
inhibit
antivir
type
interferon
product
result
interferonstimul
gene
isg
product
famili
regul
variou
cellular
event
cell
metabol
prolifer
surviv
major
function
phosphoryl
membran
phospholipid
activ
gener
phosphoryl
function
second
messeng
interact
pleckstrin
homolog
domaincontain
protein
aktpkb
phosphoinositidedepend
kinas
pdk
cell
treat
inhibitor
show
significantli
decreas
influenza
viru
titer
suggest
perform
influenzasupport
function
infect
influenza
viru
lead
activ
varieti
differ
mapk
cascad
activ
varieti
extracellular
stimuli
growth
factor
cytokin
environment
stress
factor
like
osmot
stress
ultraviolet
light
downstream
substrat
mapk
transcript
factor
eg
cjun
protein
kinas
map
kinaseactiv
protein
kinas
therebi
mapk
pathway
regul
varieti
cellular
respons
gene
express
prolifer
differenti
apoptosi
immun
respons
influenza
ribonucleoprotein
rnp
format
nuclear
export
import
step
life
cycl
influenza
viru
data
indic
rafmekerk
cascad
requir
effici
nuclear
rnp
export
indic
sever
studi
inhibit
raf
signal
result
nuclear
retent
viral
rnp
concomit
inhibit
viru
product
influenza
viru
ha
membran
accumul
tight
associ
lipid
raft
domain
trigger
activ
mapk
cascad
via
activ
rnp
export
ha
membran
accumul
enhanc
higher
polymeras
activ
influenza
viru
result
upregul
mapk
cascad
effici
nuclear
rnpexport
along
viru
product
addit
mapk
jnk
shown
regul
express
proinflammatori
cytokin
influenza
virusinfect
cell
import
influenza
virusinduc
signal
mediat
transcript
factor
nfb
factor
regul
express
varieti
antivir
cytokin
includ
initi
strong
type
ifn
defens
program
although
nfb
gener
regard
central
factor
innat
immun
defens
two
independ
studi
demonstr
replic
influenza
virus
impair
rather
enhanc
cell
pathway
block
nfb
act
via
induct
proapoptot
factor
tnfrelat
apoptosisinduc
ligand
trail
fasl
subsequ
activ
caspas
result
enhanc
export
viral
rnp
nucleu
presum
specif
cleavag
nuclear
pore
protein
result
enhanc
diffus
rnp
pore
lastli
nfb
differenti
regul
viral
rna
synthesi
mechan
may
contribut
differ
extent
enhanc
effect
nfb
viru
propag
therebi
identifi
factor
potenti
target
antivir
intervent
besid
direct
antivir
action
nfb
inhibit
may
also
indirectli
influenc
fact
exacerb
pathogenesi
influenza
viru
sinc
major
cytokineschemokin
induc
infect
highli
pathogen
virus
regul
nfb
summar
host
cell
pathway
overlap
identifi
among
rnai
screen
influenza
viru
tabl
indic
core
cell
signal
process
coopt
influenza
viru
variabl
specif
gene
hit
list
differ
screen
like
explain
variat
efficaci
knockdown
specif
gene
target
differ
rnai
librari
variat
time
individu
screen
assay
factor
relat
assay
rnai
screen
demonstr
enorm
potenti
improv
understand
hostpathogen
interact
sever
challeng
remain
describ
one
issu
focus
lack
overlap
associ
hit
identifi
across
differ
screen
differ
viral
subtyp
host
cell
assay
type
reagent
may
respons
differ
date
definit
studi
address
discrep
sever
practic
could
offset
challeng
associ
dispar
hit
list
one
would
follow
direct
research
microarray
field
develop
consist
set
minimum
inform
standard
complement
central
publicli
access
portal
data
submiss
review
minimum
inform
rnai
experi
miar
http
miar
sourceforgenet
standard
concept
rnai
screen
advoc
publish
screen
data
includ
extens
experiment
detail
regard
target
cell
sourc
deliveri
method
assay
design
plate
layout
reagent
composit
control
metric
data
analysi
databas
establish
submiss
miarecompli
rnai
screen
ongo
develop
miar
standard
codevelop
pubm
databas
rnai
screen
repres
import
progress
communitywid
adopt
miar
standard
submiss
polici
yet
achiev
revit
collabor
effort
academ
govern
industri
partner
would
greatli
acceler
accept
implement
miar
therebi
facilit
commun
abil
address
question
regard
screen
reproduc
second
practic
could
address
issu
dispar
hit
list
pertain
effort
hit
valid
case
sirna
pool
use
primari
screen
deconvolut
pool
identif
instanc
individu
sirna
singl
pool
induc
phenotyp
use
valid
case
valid
employ
use
complet
differ
set
sirna
target
differ
seed
site
gene
use
shrna
multipl
screen
assay
multipl
viral
strain
bioinformat
complet
differ
genesilenc
technolog
exampl
small
molecul
whether
hit
valid
procedur
consid
equal
open
debat
howev
adopt
standard
valid
method
may
bring
greater
pariti
screen
relat
techniqu
employ
hit
valid
criteria
use
identifi
primari
hit
screen
date
defin
hit
base
plate
mean
standard
deviat
mean
rel
neg
control
howev
recent
studi
separ
paramet
use
compil
hit
signatur
improv
concord
previou
screen
increas
valid
hit
secondari
experi
major
goal
rnai
hostpathogen
screen
identifi
host
gene
pathway
facilit
viral
replic
import
note
analog
technolog
use
address
question
compound
screen
microarray
ng
screen
smallmolecul
inhibitor
drug
compound
librari
screen
involv
highthroughput
analysi
potenti
pharmacolog
agent
modul
biolog
pathway
sometim
specif
host
gene
major
advantag
compound
librari
screen
larg
number
candid
compound
sometim
million
come
bioactiv
commerci
academ
natur
extract
librari
screen
antivir
potenti
often
without
need
deliveri
reagent
although
major
limit
often
lack
inform
compound
screen
provid
cellular
target
mechan
link
antivir
activ
advanc
screen
technolog
platform
compens
exampl
highcont
analysi
method
use
imag
live
cell
basic
unit
molecul
discoveri
track
quantit
provid
qualit
inform
protein
interest
present
cell
use
fluoresc
tag
green
fluoresc
protein
fluoresc
antibodi
imag
analysi
use
measur
chang
properti
cell
caus
treatment
candid
compound
chemic
inhibitor
rna
interfer
howev
import
note
compound
librari
screen
often
complic
need
perform
analys
multipl
compound
concentr
address
toxic
concern
cell
death
could
mistakenli
identifi
efficaci
problem
associ
compound
smallmolecul
librari
screen
includ
poor
solubl
drug
poor
andor
variabl
cellular
uptak
drug
specif
issu
despit
concern
number
compound
librari
screen
conduct
madindarbi
canin
kidney
mdck
cell
identifi
influenza
inhibitor
result
led
followup
valid
studi
human
cell
microarray
use
extens
studi
host
pathway
implic
viru
life
cycl
inform
understand
viral
pathogenesi
first
report
microarray
studi
hostinfluenza
viru
interact
express
level
gene
measur
hela
cell
respons
live
heatinactiv
influenza
exposur
differenti
express
gene
identifi
infect
major
downregul
could
classifi
main
groupsprotein
synthesi
cytokin
signal
ubiquitin
pathway
factor
mrna
process
export
protein
transcript
factor
broad
comparison
gene
famili
pathway
show
reason
level
complementar
identifi
recent
rnai
screen
experi
perform
use
microarray
technolog
identifi
number
host
pathway
impact
rang
virus
includ
hiv
human
papillomaviru
herp
simplex
viru
treatment
ifn
studi
provid
valuabl
inform
regard
host
pathway
provid
new
candid
antivir
therapi
despit
larg
amount
microarray
data
infrastructur
avail
research
appear
ng
may
supersed
technolog
due
mainli
improv
transcriptom
coverag
sensit
resolut
sinc
microarray
limit
genom
coverag
probe
set
ng
advantag
identifi
express
chang
poorli
character
transcript
particularli
small
noncod
rna
famili
ngsgener
genomewid
express
profil
host
cell
emerg
number
virus
includ
mimiviru
vaccinia
viru
hiv
studi
provid
global
view
host
genom
impact
viral
infect
addit
chang
viru
gene
express
level
infect
ng
analys
host
cell
respons
influenza
infect
eagerli
anticip
import
distinct
inform
base
lossoffunct
result
rnaimedi
gene
silenc
microarray
sequenc
approach
provid
detail
readout
fold
chang
gene
express
may
determin
import
specif
gene
biolog
process
may
ignor
import
gene
pathway
low
level
chang
express
observ
follow
infect
technolog
allow
screen
proteinprotein
proteindna
interact
screen
identifi
proteinprotein
interactom
network
epsteinbarr
viru
sarslik
coronaviru
hepat
c
viru
infect
comprehens
studi
recent
conduct
intravir
proteinprotein
interact
analyz
technolog
influenza
viru
protein
addit
interact
viral
protein
human
protein
human
orfeom
influenza
gene
segment
known
interact
host
pathway
disrupt
antivir
action
review
ref
numer
novel
contact
host
protein
np
influenza
gene
segment
identifi
studi
elegantli
combin
rnai
technolog
identifi
host
protein
pathway
involv
physic
recognit
influenza
protein
result
pathway
mediat
antivir
respons
import
influenza
viru
global
human
anim
health
coupl
current
limit
associ
vaccin
product
antivir
therapeut
pipelin
underscor
need
novel
solut
acceler
develop
viru
intervent
strategi
genomewid
rnai
screen
emerg
technolog
power
detail
hostviru
interact
further
understand
viru
pathogenesi
therebi
drive
develop
nextgener
antivir
basi
find
metaanalys
influenza
screen
like
influenza
viru
princip
coopt
host
gene
late
viru
replic
succinctli
influenza
viru
carri
necessari
protein
infect
cell
deliv
vrnp
cell
nucleu
howev
viral
protein
synthes
cytoplasm
thu
viru
must
use
host
protein
pathway
import
np
rna
polymeras
back
nucleu
form
new
vrnp
likewis
assembl
influenza
compon
occur
plasma
membran
requir
host
mechan
move
new
vrnp
nucleu
cytoplasm
traffic
viral
protein
compon
toward
membran
assembl
packag
new
virion
hypothesi
consist
subtl
differ
observ
viral
genom
express
rel
huge
differ
observ
highcont
analysi
viru
replic
addit
metaanalys
studi
host
factor
link
regul
cell
death
affect
influenza
viru
featur
like
requir
facilit
replic
given
scale
inform
gener
rnai
screen
critic
import
benefici
collabor
research
arena
admir
exampl
scientif
consortia
center
compos
dispers
network
laboratori
success
work
togeth
achiev
signific
goal
us
nation
institut
allergi
infecti
diseas
center
excel
influenza
research
surveil
human
genom
project
provid
two
exampl
intervent
strategi
tackl
academ
govern
industri
entiti
worldwid
repres
good
exampl
dispar
entiti
work
partnership
toward
common
goal
similarli
effort
organ
rnai
global
initi
design
tackl
challeng
repres
eid
influenza
benefit
human
health
vital
success
emerg
field
collabor
initi
promot
develop
data
standard
best
practic
facilit
comparison
data
complementari
screen
lead
better
understand
factor
strongli
influenc
screen
reproduc
data
qualiti
ultim
improv
potenti
rnai
technolog
identifi
optim
antiviraldrug
candid
